Victoza® / Saxenda®
Liraglutide is a GLP-1 receptor agonist with 97% amino acid homology to native GLP-1. Used for type 2 diabetes and weight management.
| Dosage Form | SC Injectable (Prefilled Pen) |
| Strength | 6 mg/mL pen (Victoza); 6 mg/mL pen (Saxenda) |
| Storage | Store at 2–8°C. After first use, store at 15–30°C for up to 30 days. |
| Category | Diabetes & GLP-1 |
| Availability | Available for Transfer |
Type 2 diabetes mellitus; chronic weight management; cardiovascular risk reduction in T2DM patients with established CVD.
GLP-1 receptor agonist that increases insulin secretion, decreases glucagon secretion in a glucose-dependent manner, slows gastric emptying, and reduces appetite.
Each Burrard Pharmaceuticals technology transfer package for Liraglutide includes comprehensive documentation and support:
Complete formulation with manufacturing parameters, excipient specifications, and process controls.
Validated methods for assay, impurities, dissolution, and stability-indicating analysis.
Market-ready regulatory dossier sections for a named territory, scoped per programme.
ICH-compliant stability studies (accelerated and long-term) with detailed protocols.
Scale-up procedures, batch records, equipment specifications, and in-process controls.
Direct advisory access to formulation scientists and regulatory specialists throughout transfer.
Scope and timing for the complete know-how package are confirmed in writing after a confidentiality agreement. Book a consultation to discuss your specific requirements.